8C7 : A Fully Human Anti‐ PTGFRN Monoclonal Antibody‐Drug Conjugate Inhibiting Tumour Growth of Mesothelioma and Paediatric Medulloblastoma Cell Lines
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Jorge Marquez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Maryland, Baltimore School of Pharmacy, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Immunoconjugates, Antibodies, Monoclonal, Medulloblastoma. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Antibody Drug Conjugates (ADCs) are attractive for developing cancer‐targeted therapies, particularly for cancers with unmet needs. Identification of a druggable internalising cell‐surface target enables the development of internalising monoclonal antibodies to deliver toxic payloads directly to the cancer cells. Using immunohistochemistry, we screened various non‐cancerous and cancerous tissue sections to assess PTGFRN expression levels. We produced hybridoma lines that produce fully human antibodies against the PTGFRN extracellular domain. After screening, we conjugated the cytotoxic payload Duocarmycin to an antibody candidate and tested its efficacy in in vitro assays, as well as in vivo xenografted athymic nude mice. We showed that PTGFRN expression was undetectable in non‐cancerous tissue samples and overexpressed in several patient‐derived cancer tissue samples. We produced a hybridoma line that produces a fully human IgG1 (8C7) against PTGFRN. 8C7 binds to cell‐surface PTGFRN, inducing endocytosis of PTGFRN. Direct conjugation of Duocarmycin to 8C7 resulted in an antibody‐drug conjugate that showed high potency in in vitro and in vivo models for three PTGFRN‐expressing cell lines examined, A431, DAOY, and MSTO, while it had no effect on PTGFRN‐negative MDA‐MB‐231. 8C7‐ADC administered via intraperitoneal injection to xenografted mice showed inhibition of tumour formation and growth with no effect on body weight and organ weights. These findings further validate PTGFRN as a target for antibody‐drug conjugate development for cancers with unmet needs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Maryland, Baltimore School of Pharmacy, Baltimore, Maryland, USA.
- Target Discovery Division, A&G Pharmaceutical, Inc., Columbia, Maryland, USA.
- Precision Antibody, Columbia, Maryland, USA.
- Trans Chromosomics, Inc. Yonago, Tottori, Japan.
ORCID-Profile: Ginette Serrero
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Marquez, J., Dong, J., Yue, B., Hayashi, J., Dong, C., Oshimura, M., & Serrero, G. (2025). 8C7 : A Fully Human Anti‐ PTGFRN Monoclonal Antibody‐Drug Conjugate Inhibiting Tumour Growth of Mesothelioma and Paediatric Medulloblastoma Cell Lines. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70665
Vancouver
Marquez J, Dong J, Yue B, Hayashi J, Dong C, Oshimura M, et al. 8C7 : A Fully Human Anti‐ PTGFRN Monoclonal Antibody‐Drug Conjugate Inhibiting Tumour Growth of Mesothelioma and Paediatric Medulloblastoma Cell Lines. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70665
BibTeX
@article{Marquez2025,
author = {Marquez, Jorge and Dong, Jianping and Yue, Binbin and Hayashi, Jun and Dong, Chun and Oshimura, Mitsuo and Serrero, Ginette},
title = {8C7 : A Fully Human Anti‐ PTGFRN Monoclonal Antibody‐Drug Conjugate Inhibiting Tumour Growth of Mesothelioma and Paediatric Medulloblastoma Cell Lines},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70665}
}
EUVIMED